HAIKOU CITY, China, Sept. 11, 2019 /PRNewswire/ — China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," "CPHI", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that it has entered into a Memorandum of Understanding (MOU) and the Addendum with World Health Advanced Technologies, Ltd (W.H.A.T.) to advance the scientific success of ENERCEL® on an exclusive basis in China.
Chinese government has had the foresight to approve and develop the Free Trade Zone of Hainan Island. On top of that, BOAO Lecheng International Medical Tourism Pilot Zone has had the foresight to approve the concept and get the job done, which brought new medical technologies to people who are suffering from diseases in China.
Ms. Zhilin Li, CEO of China Pharma, and the rest of the Company’s management are excited about bringing this treatment to China, which is consistent with the mission of China Pharma and Chinese government of providing basic medical solutions to patients who are in need of such treatment. The Company’s wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., was founded in 1993 in Haikou City, Hainan Province, China, with more than 20 years’ experience in Chinese pharmaceutical industry. CPHI looks toward to expanding this vital business relationship and providing medical support to all of the patients in China and the rest of Asia. We believe ENERCEL®, along with CPHI’s GMP facility, shall place China Pharma as one of the significant leaders in advancing the national mission of China, which is "to make China a healthy nation by fully developing the health industry through new medical technologies."
World Health Advanced Technologies, Ltd. is dedicated to providing ENERCEL® preparations to people who are interested in achieving and maintaining the bio-functional health of our bodies.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective, business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, the adaptability of potential cooperative products/technologies to relevant laws and regulations of the target market, the actual clinical effects of potential cooperative products/technologies, and the progress of commercial negotiations between the two parties, and such other factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations except as required by applicable law or regulation.
Related Links :